Lite Strategy, Inc. (LITS)

Lite Strategy, Inc. is a company that holds Litecoin as its primary treasury reserve asset. It was formerly known as MEI Pharma, a biopharmaceutical company, and adopted its new name after shifting its strategy in 2025 to acquiring and holding Litecoin, with involvement from figures associated with the Litecoin project.

The company's approach is to use its capital and capital-raising activities to accumulate Litecoin over time, giving shareholders exposure to the cryptocurrency through a listed company. It has also continued to manage remaining assets from its earlier drug development activities.

Lite Strategy is based in San Diego, California, and its common stock trades on the Nasdaq under the ticker LITS.